EP2863890A1 - Formulation de fénofibrate - Google Patents

Formulation de fénofibrate

Info

Publication number
EP2863890A1
EP2863890A1 EP20120880074 EP12880074A EP2863890A1 EP 2863890 A1 EP2863890 A1 EP 2863890A1 EP 20120880074 EP20120880074 EP 20120880074 EP 12880074 A EP12880074 A EP 12880074A EP 2863890 A1 EP2863890 A1 EP 2863890A1
Authority
EP
European Patent Office
Prior art keywords
granules
fenofibrate
weight
surfactant
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20120880074
Other languages
German (de)
English (en)
Other versions
EP2863890A4 (fr
Inventor
Sarat C. Chattaraj
Glenn Allen Redelman
Andrew Alan Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Inc
Original Assignee
Mylan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Inc filed Critical Mylan Inc
Publication of EP2863890A1 publication Critical patent/EP2863890A1/fr
Publication of EP2863890A4 publication Critical patent/EP2863890A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Definitions

  • This invention relates generally to immediate release fenofibrate dosage forms.
  • Fenofibrate is an active principle which is very poorly soluble in water, and the absorption of fenofibrate in the digestive tract is limited. An increase in its solubility leads to better digestive absorption.
  • Various approaches have been explored in order to increase the solubility of fenofibrate, including micronization of the active principle, addition of a surfactant, and comicronization of fenofibrate with a surfactant.
  • Fenofibrate is freely soluble in methanol and acetonitrile, and insoluble in water. Having no ionizable group, fenofibrate solubility is not influenced by changes in medium pH. However, the aqueous solubility of Fenofibrate can be improved in the presence of surfactants. As the concentration of the surfactant sodium lauryl sulfate, for example, increases from 0.0 M to 0.1 M, fenofibrate solubility increases from 0.8 mg/L to 910.8 mg/L.
  • U.S. Patent Number 4,800,079 (January 24, 1989, Jean-Francois Boyer) describes a granular medicine based on fenofibrate, each granule comprising an inert core, a layer based on fenofibrate, and a protective layer.
  • the medicine is characterized in that the fenofibrate is present in the form of crystalline microparticles having a size of less than 30 microns, and preferably less than 10 microns.
  • the layer based on fenofibrate includes a binder selected from the group consisting of methacrylic polymers, polyvinylpyrolidone, cellulose derivatives, and polyethylene glycols.
  • U.S. Patent Number 7,101,574 (September 5, 2006, Bruno Criere et.al.) describes a pharmaceutical composition containing micronized fenofibrate, a surfactant and a cellulose derivative as a binder, preferably hydroxypropylmethylcellulose.
  • the cellulose derivative represents less than 20 wt. % of the composition, while the fenofibrate is present in an amount greater than or equal to 60% by weight of the pharmaceutical composition.
  • the disclosed formulation provides enhanced bioavailability of the active principle.
  • EP Patent 0256933 describes fenofibrate granules containing micronized fenofibrate to increase fenofibrate bioavailability.
  • the fenofibrate microparticles are less than 50 micron in size, and polyvinylpyrrolidone is used as a binder.
  • the document describes other types of binder, such as methacrylic polymers, cellulose derivatives and polyethylene glycols.
  • EP Patent 0330532 describes improving the bioavailability of fenofibrate by comicronizing it with a surfactant, such as sodium lauryl sulfate.
  • the comicronized product is then granulated by wet granulation in order to improve the flow capacities of the powder and to facilitate the transformation into gelatin capsules.
  • This comicronization allows a significant increase in the bioavailability compared to the use of fenofibrate described in EP 0256933.
  • the granules described in EP 0330532 contain polyvinylpyrrolidone as a binder.
  • EP 0330532 teaches that the comicronization of fenofibrate with a solid surfactant improves the bioavailability of fenofibrate compared to either micronized fenofibrate, or to the combination of a surfactant and of micronized fenofibrate.
  • the formulation of EP 0330532 is unsatisfactory, as it does not provide complete bioavailability of the active ingredient.
  • the technique of co- micronizing fenofibrate with a solid surfactant improves dissolution of fenofibrate, but still produces incomplete dissolution.
  • Various embodiments disclosed herein relate to a dosage form comprising an effective amount of fenofibric acid, pharmaceutically acceptable salts thereof, pharmaceutically acceptable esters thereof, or prodrugs thereof.
  • the active agent is fenofibrate, an ester of fenofibric acid which is hydrolyzed to fenofibric acid in vivo.
  • Fenofibrate is a prodrug of fenofibric acid.
  • a fenofibrate formulation comprises a population of low bioavailability fenofibrate-containing beads (slow beads), and a population of high bioavailability fenofibrate-containing beads (fast beads).
  • a portion of the desired fenofibrate dose is included in the slow beads, and the remainder of the desired fenofibrate dose is included in the fast beads.
  • the fast and slow beads are combined to produce a single dosage form having a desired bioavailability, as measured by the rate and extent of absorption. Specifically, the rate and extent of absorption is measured by the parameters AUCL, AUCI, and Cpeak.
  • the parameter AUCL is the area under the plasma concentration-time curve from time zero to time t, where t is the last time point with measurable concentration for individual formulation.
  • the parameter AUCI is the area under the plasma concentration-time curve from time zero to time infinity. Additionally, Cpeak is the maximum plasma concentration of the drug.
  • the overall bioavailability of the dosage form may be modulated by the presence of low bioavailability fenofibrate-containing beads.
  • the dosage form comprises a plurality of first granules and a plurality of second granules combined in a weight ratio of said first granules to said second granules of between about 50:50 and about 90: 10, where the dosage form provides a peak plasma concentration of fenofibric acid of between 4000 ng/mL and 4800 ng/mL fenofibrate when administered to a human subject.
  • a first comparative dosage form comprising 100% of first granules provides a peak plasma concentration of fenofibric acid of greater than 4800 ng/mL, when administered to a human subject; and a second comparative dosage form comprising 100% of second granules provides a peak plasma concentration of fenofibric acid of less than 3500 ng/mL when administered to a human subject.
  • Various embodiments relate to a pharmaceutical composition having a target bioavailability in vivo, where the pharmaceutical composition comprises a plurality of first granules having a first bioavailability in vivo, and a plurality of second granules having a second bioavailability in vivo which is less than said first bioavailability, said target bioavailability being between said first bioavailability and said second bioavailability.
  • the first granules comprise fenofibrate, a first surfactant, and a first water soluble or water dispersible cellulose derivative; and said second granules comprise fenofibrate; an optional second surfactant; and a second water soluble or water dispersible cellulose derivative.
  • the pharmaceutical composition comprises from 50% to 90% of the first granules, based on the combined weight of the first and second granules; and from 10% to 50% of the second granules, based on the combined weight of the first and second granules.
  • the pharmaceutical composition may comprise at least one pharmaceutically inactive excipient or additive, in addition to the first and second granules.
  • the first bioavailability in vivo is the bioavailability of a comparative dosage form comprising 100% of said first granules and 0% of said second granules; and the second bioavailability in vivo is the bioavailability of a comparative dosage form comprising 0% of said first granules and 100% of said second granules.
  • an immediate release pharmaceutical composition comprising a plurality of first granules comprising a first composition, where the first composition includes fenofibrate, from 0.3% to 10% by weight of the first granules of a first surfactant, and a first water soluble or water dispersible cellulose derivative; and a plurality of second granules comprising a second composition including fenofibrate, from 0% to 0.25% by weight of the second granules of a second surfactant, and a second water soluble or water dispersible cellulose derivative.
  • each first granule comprises an inert core coated with a layer of the first composition; and each second granule comprises an inert core coated with the second composition.
  • Various embodiments disclosed herein relate to a pharmaceutical composition
  • a pharmaceutical composition comprising a plurality of first granules having a first coating, where the first coating has a high bioavailability in vivo, in combination with a plurality of second granules having a second coating, where the second coating has a low bioavailability in vivo.
  • the first coating comprises fenofibrate, from 0.3% to 10% by weight of said first granules of a first surfactant, and a first water soluble or water dispersible cellulose derivative, while the second coating comprising fenofibrate, from 0% to 0.25% by weight of said second granules of a second surfactant, and a second water soluble or water dispersible cellulose derivative.
  • the first coating comprises from 0.3% to 10% by weight of the first granules of the first surfactant
  • the second coating comprises from 0% to 0.05%, preferably 0%, by weight of the second granules of the second surfactant.
  • the first surfactant is the same as the second surfactant. In other embodiments, the first surfactant is different from the second surfactant. Similarly, the first cellulose derivative and the second cellulose derivative may be the same or different.
  • the first and second surfactants may be anionic surfactants, nonionic surfactants, or cationic surfactants, preferably anionic surfactants.
  • a preferred surfactant is sodium lauryl sulfate.
  • a pharmaceutical composition comprising a plurality of first coated granules, where each first coated granule includes a first inert core coated with a first composition comprising fenofibrate and a first water soluble or water dispersible cellulose derivative.
  • the fenofibrate and the first cellulose derivative are present in said first composition in a weight ratio of from about 1 : 1 to less than 5: 1.
  • the pharmaceutical composition additionally comprises a plurality of second coated granules, each second granule including a second inert core coated with a second composition comprising fenofibrate and a second water soluble or water dispersible cellulose derivative, where the fenofibrate and the second cellulose derivative are present in a weight ratio of from greater than 5: 1 to about 15: 1.
  • the fenofibrate and the first cellulose derivative are present in the first composition in a weight ratio of from about 2: 1 to about 4.5: 1, preferably from about 3.5: 1 to about 4.5: 1; and the fenofibrate and the second cellulose derivative are present in the second composition in a weight ratio of from about 6: 1 to about 12: 1, preferably from about 7: 1 to about 9: 1.
  • Various embodiments disclosed herein relate to a dosage form which is bioequivalent to ANTARA® capsules having an equivalent amount of fenofibrate.
  • the bioequivalent dosage form comprising a defined amount of fenofibrate, which may be between 40 and 200 mg fenofibrate, preferably between 40 and 160 mg micronized fenofibrate.
  • the dosage form comprises a first composition and a second composition being combined in a weight ratio of said first composition to said second composition of between about 50:50 and about 90: 10, preferably between 60:40 and 90: 10, most preferably between about 75:25 and 80:20.
  • the first composition has a high bioavailability and the second composition has a low bioavailability.
  • bioequivalence depends on several natural log transformed parameters associated with the rate and extent of absorption. Specifically, bioequivalence depends on the parameters AUCL and AUCI. The parameters AUCL and AUCI must fall between 80 and 125% of the corresponding values for the branded product for therapeutic equivalence. Additionally, the maximum plasma concentration, Cpeak, must fall between 80% and 125% of the corresponding Cpeak of the branded product for therapeutic equivalence.
  • the bioequivalent dosage form disclosed herein containing the first composition and the second composition, when administered to a human subject, provides a peak plasma concentration Cpeak of fenofibric acid which is between 80% and 125% for the 90% confidence interval for Cpeak value obtained with ANTARA® capsules having an equivalent amount of fenofibrate,.
  • a first comparative dosage form comprising 100% of the first composition provides a Cpeak of fenofibric acid which is between 105% and 160% of a Cpeak value obtained with said ANTARA® capsules, within a 90% confidence interval; while a second comparative dosage form comprising 100% of said second composition provides a Cpeak of fenofibric acid of less than 80% of a Cpeak value obtained with said ANTARA® capsules, within a 90% confidence interval.
  • the first comparative dosage form comprising 100% of said first composition provides a Cpeak of fenofibric acid which is between 105% and 140% for the 90% confidence interval for Cpeak value obtained with said ANTARA® capsules,; and the second comparative dosage form comprising 100% of said second composition provides a Cpeak of fenofibric acid of between 40% and 80% for the 90% confidence interval for Cpeak value obtained with said ANTARA® capsules.
  • the dosage form when administered to a human subject, provides a value of AUCL for fenofibric acid which is between 80% and 125% for the 90% confidence interval for AUCL value obtained with the ANTARA® capsules having an equivalent amount of fenofibrate, and a value of AUCI for fenofibric acid which is between 80% and 125% for the 90% confidence interval for AUCI value obtained with the ANTARA® capsules having an equivalent amount of fenofibrate.
  • Various embodiments disclosed herein relate to the manufacture of Fenofibrate Capsules containing between 40 mg and 200 mg fenofibrate, preferably between 40 mg and 160 mg micronized fenofibrate.
  • the manufacture of Fenofibrate Capsules involves manufacture of Fenofibrate Intermediate Beads having a slow drug release rate via rotor drug layering of an aqueous suspension of HPMC and fenofibrate particles onto inert core material, followed sequentially by fluidized bed drying, and screening the coated core material to control particle size.
  • the ratio of drug to HPMC in these slow release beads is 8: 1; the slow release beads do not contain surfactant.
  • the manufacture of Fenofibrate Capsules further involves manufacture of Fenofibrate Intermediate Beads having a fast drug release rate via rotor drug layering of an aqueous suspension of HPMC and fenofibrate particles onto inert core material, followed sequentially by fluidized bed drying, and screening the coated core material to control particle size.
  • the ratio of drug to HPMC in these fast release beads is 4: 1 ; the fast release beads contain between about 0.5% and about 2% by weight, based on the weight of the fast release beads, of a surfactant, preferably a sodium lauryl sulfate surfactant.
  • Fenofibrate Capsules are produced by combining the fast release beads and the slow release beads to form a mixture, and encapsulating the mixture in a gelatin capsule shell.
  • Fenofibrate Capsules may be produced by introducing the fast release beads and the slow release beads into a gelatin capsule shell separately, e.g., by first introducing the fast release beads into the capsule shell, and then introducing the slow release beads into the capsule shell.
  • the fast and slow release drug layered beads produced by the methods disclosed herein are free of agglomeration; achieve acceptable capsule content uniformity and potency; achieve rapid drug release from the dosage form; and achieve adequate chemical stability throughout the intended shelf life.
  • FIG. 1 and FIG. 2 show the concentration of fenofibrate in plasma over time upon administration of 130 mg ANTARA® capsules and administration of 130 mg capsules according to Example 4.
  • FIG. 3 shows the concentration of fenofibrate in plasma over time upon administration of 130 mg ANTARA capsules and administration of 130 mg capsules according to Example 6.
  • Fig. 4 shows the concentration of fenofibrate in plasma over time upon administration of 130 mg ANTARA® capsules and administration of 130 mg capsules according to Example 7.
  • FIG. 5 and FIG. 6 show the concentration of fenofibrate in plasma over time upon administration of 130 mg ANTARA® capsules and administration of 130 mg capsules according to Example 8. DETAILED DESCRIPTION
  • the high bioavailability fenofibrate-containing beads contain micronized fenofibrate, a surfactant, and a binder which is water-soluble or water-dispersible.
  • Suitable binders include hydroxypropylmethylcellulose (HPMC); hydroxypropyl cellulose; hydroxyethyl cellulose; carboxymethylcellulose; povidone and chitosan, with HPMC being a preferred binder.
  • HPMC hydroxypropylmethylcellulose
  • HPMC hydroxypropyl cellulose
  • hydroxyethyl cellulose carboxymethylcellulose
  • povidone and chitosan with HPMC being a preferred binder.
  • a suitable HPMC binder is commercially available under the trade name Pharmacoat® 603, from Harke Group.
  • the low bioavailability fenofibrate-containing beads contain micronized fenofibrate, and a binder which is water-soluble or water-dispersible.
  • Suitable binders include hydroxypropylmethylcellulose (HPMC); hydroxypropyl cellulose; hydroxyethyl cellulose; carboxymethylcellulose; povidone and chitosan, with HPMC being a preferred binder.
  • the high bioavailability fenofibrate-containing beads contain a surfactant in an amount of between about 0.3% by weight and about 10% by weight, preferably between about 0.5% by weight and about 5% by weight, more preferably between about 0.5% by weight and about 3% by weight.
  • the low bioavailability fenofibrate-containing beads contain a surfactant in an amount of between about 0% by weight and about 0.25% by weight, preferably between about 0% by weight and about 0.05% by weight, more preferably 0% by weight.
  • the low bioavailability fenofibrate-containing beads (slow beads) and the high bioavailability fenofibrate-containing beads (fast beads) may be co-administered in a single dosage form.
  • the low bioavailability fenofibrate-containing beads and the high bioavailability fenofibrate-containing beads may be combined and filled into a hard gelatin shell to form a capsule.
  • Such compressed tablets may include a combination of slow beads and fast beads mixed together and combined with the binder and excipients prior to compression.
  • slow beads may be mixed with the binder and excipients prior to a first compression step to form a first layer containing slow beads; and then the fast beads may be combined with the binder and excipients prior to a second compression step.
  • the formulation of fast beads and binder is deposited on the first layer, and the formulation of fast beads is compressed to form a bilayer tablet.
  • suitable colorants may be added to either or both of the slow bead formulation and the fast bead formulation so that the layers of the bilayer tablet are visually distinguishable.
  • the formulation of fast beads may be compressed initially to form the first layer, with the second layer containing the formulation of slow beads.
  • the fast beads and the slow beads may be combined, and then blended with suitable excipients, including a binder, a water-soluble or water- dispersible filler, a disintegrant and/or a lubricant.
  • suitable excipients including a binder, a water-soluble or water- dispersible filler, a disintegrant and/or a lubricant.
  • the resulting mixture may be compressed into multiple mini-tablets, which may then be then encapsulated in a suitable size two piece hard gelatin capsule shell.
  • the fast beads may be blended with suitable excipients, and then compressed into multiple mini-tablets.
  • the slow beads may be blended with suitable excipients, and then compressed into multiple mini-tablets.
  • Mini- tablets containing the fast beads may be mixed with mini-tablets containing the slow beads, and the resulting admixture may then be then encapsulated in a suitable size two piece hard gelatin capsule shell.
  • the mini-tablets containing the fast beads and the mini-tablets containing the slow beads contain equal amounts of fenofibrate, and are combined in a predetermined ratio.
  • a capsule containing mini-tablets containing fast beads and mini-tablets containing slow beads contains from 50% to 80% of mini-tablets containing fast beads and from 20% to 50% of mini-tablets containing the slow beads.
  • the dosage of fenofibrate may take the form of multiple tablets to be coadministered.
  • a first tablet may contain fenofibrate in the form of fast beads only (a fast tablet), while a second tablet may contain fenofibrate in the form of slow beads only (a slow tablet).
  • one slow tablet may be coadministered with at least one fast tablet, preferably from one to three fast tablets.
  • one tablet containing fast beads or a combination of slow and fast beads may be prepared as disclosed herein, and then combined with a granulated powder of fenofibrate and encapsulated in a suitable size two piece hard gelatin capsule shell.
  • a combination of fast beads and granulated powder of fenofibrate can be encapsulated to achieve the desired drug release profile.
  • the slow and fast beads can also be manufactured by extrusion spheronization technology.
  • the dosage forms disclosed herein may be manufactured from granules manufactured by spray drying techniques. For example, a slurry of fenofibrate, a cellulosic binder, and a surfactant in an amount of between about 0.3% by weight and about 10% by weight, based on solids content, may be spray dried to form fast granules.
  • a slurry of fenofibrate, a cellulosic binder, and a surfactant in an amount of between about 0% by weight and about 0.25% by weight, based on solids content, may be spray dried to form slow granules.
  • the fast and slow granules may be used as substitutes for fast and slow beads.
  • the fenofibrate beads or granules can be used for manufacturing combination pharmaceutical products.
  • the combination products may contain fenofibrate and a second drug, such as a statin, niacin, or metformin.
  • the combination products may be manufactured by applying a fenofibrate suspension onto a core material, where the core material contains at least one pharmaceutical active, such as a statin, niacin, or metformin.
  • the slow and fast beads may be combined and filled into a unit dose sealed pouch.
  • the contents of the pouch may be dispersed in a liquid such as juice or water, and the patient may drink the resulting dispersion.
  • the ratio of the fast and slow beads (fast beads: slow beads) in the dosage forms disclosed herein is between 50:50 and 90: 10, preferably between 60:40 and 90: 10, most preferably between about 75:25 and 80:20.
  • the beads disclosed herein may be prepared by spraying the drug layer suspension onto inert cores, preferably inert cores having a 20 to 50 mesh particle size, i.e., 300 microns to 850 microns.
  • the inert cores may have a mesh size of 20 to 25, i.e., from 700 to 850 microns.
  • the inert cores may have a mesh size of 35 to 45, i.e., from 350 to 500 microns.
  • the fast beads may be made from inert cores having a mesh size of between 20 mesh and 25 mesh, while the slow beads may be made from inert cores having a mesh size of between 35 mesh and 45 mesh. In other embodiments, the fast beads may be made from 35 to 45 mesh cores, while the slow beads may be made from 20 to 25 mesh cores.
  • an HPMC binder is solubilized in water or a polar organic solvent.
  • Micronized fenofibrate is added to the binder solution to form a drug suspension.
  • the surfactant is added to the drug suspension.
  • an antifoaming agent is incorporated into the drug suspension.
  • Suitable antifoaming agents include silicones, such as dimethicone.
  • Suitable solvents include Class 3 solvents, i.e., solvents of low toxic potential.
  • Preferred Class 3 solvents include polar solvents suitable for dissolving or dispersing HPMC, such as water, Acetone, Anisole, 1 -Butanol, 2-Butanol, 3-Methyl-l- butanol, Methyl ethyl ketone, Methyl isobutyl ketone, 2-Methyl-l-propanol, Dimethyl sulfoxide, Ethanol, 1-Pentanol, 1-Propanol, and 2-Propanol, and mixtures thereof.
  • the resulting drug suspension is homogenized, and then sprayed onto the sugar spheres.
  • the drug suspension is homogenized for a minimum of 8 hours, preferably 8 to 48 hours, more preferably 8 to 24 hours, most preferably 8 to 10 hours, prior to spraying onto the inert cores.
  • the beads disclosed herein may be prepared by spraying the drug layer suspension onto inert cores made from insoluble inert materials, such as silicon dioxide, calcium phosphate dihydrate, dicalcium phosphate, calcium sulfate dihydrate, microcrystalline cellulose, cellulose derivatives, calcium carbonate, dibasic calcium phosphate anhydrous, dibasic calcium phosphate monohydrate, tribasic calcium phosphate, magnesium carbonate, magnesium oxide and activated carbon.
  • insoluble inert materials such as silicon dioxide, calcium phosphate dihydrate, dicalcium phosphate, calcium sulfate dihydrate, microcrystalline cellulose, cellulose derivatives, calcium carbonate, dibasic calcium phosphate anhydrous, dibasic calcium phosphate monohydrate, tribasic calcium phosphate, magnesium carbonate, magnesium oxide and activated carbon.
  • the beads disclosed herein may be prepared by spraying the drug layer suspension onto soluble cores, such as sugar spheres, more particularly, spheres of sugars selected from the group consisting of like dextrose, lactose, anhydrous lactose, spray-dried lactose, lactose monohydrate, mannitol, starches, sorbitol, and sucrose.
  • soluble cores such as sugar spheres, more particularly, spheres of sugars selected from the group consisting of like dextrose, lactose, anhydrous lactose, spray-dried lactose, lactose monohydrate, mannitol, starches, sorbitol, and sucrose.
  • Other materials which may be used as inert cores include insoluble inert plastic materials, such as spherical or nearly spherical core beads of polyvinylchloride or polystyrene. Mixtures of these core materials may be used.
  • the drug suspension is sprayed onto the inert cores contains a surfactant.
  • Suitable surfactants include anionic surfactants, nonionic surfactants, cationic surfactants, or mixtures thereof.
  • the surfactants are anionic surfactants.
  • Suitable anionic surfactants include sodium oleate, sodium dodecyl sulfate, sodium diethylhexyl sulfosuccinate, sodium dimethylhexyl sulfosuccinate, sodium di-2-ethylacetate, sodium 2-ethylhexyl sulfate, sodium lauryl sulfate; sodium undecane-3-sulfate, sodium ethylphenylundecanoate, and carboxylate soaps.
  • Preferred anionic surfactants include C8 to C24 sulfate monoester surfactants.
  • More preferred anionic surfactants include sodium 2-ethylhexyl sulfate, sodium lauryl sulfate; and sodium undecane-3-sulfate.
  • Suitable cationic surfactants include benzalkonium halide salts.
  • Suitable nonionic surfactants include C8-C28 ethoxylated alcohols, mono-, di-, and trimesters of glycerol, and Polysorbate 80.
  • low bioavailability fenofibrate-containing beads may be prepared using a different surfactant from high bioavailability fenofibrate-containing beads (fast beads).
  • the slow beads include from 0% to about 0.25% by weight of a surfactant, preferably from 0% to about 0.05% by weight of a surfactant, more preferably 0% by weight of a surfactant.
  • the fast beads include from about 0.3% to about 10% by weight of a surfactant, preferably from 0.3% to about 5% by weight of a surfactant, more preferably from about 0.5% to about 2% by weight of a surfactant.
  • the slow beads contain between about 30% and about 80% micronized fenofibrate, relative to the total weight of the slow beads.
  • the slow beads contain between about 40% and about 59% micronized fenofibrate, more preferably between about 45% and about 55% micronized fenofibrate.
  • the beads may contain between about 30% and about 59% micronized fenofibrate, relative to the total weight of the slow beads.
  • the fast beads contain between about 40% and about 59% micronized fenofibrate, more preferably between about 45% and about 55% micronized fenofibrate.
  • the fast beads disclosed herein contain fenofibrate and a binder in a ratio of fenofibrate:binder of from about 1: 1 to less than 5: 1, preferably from about 2: 1 to about 4.5: 1, more preferably from about 3.5: 1 to about 4.5: 1.
  • the binder is HPMC.
  • the fast beads disclosed herein contain fenofibrate and HPMC in a ratio of fenofibrate: HPMC of about 4: 1.
  • the fast beads additionally comprise from 0.3% to about 10% by weight of sodium lauryl sulfate, preferably from 0.5% to about 2% by weight of sodium lauryl sulfate.
  • the slow beads disclosed herein contain fenofibrate and a binder in a ratio of fenofibrate:binder of from greater than 5: 1 to about 15: 1, preferably from about 6: 1 to about 12: 1, more preferably from about 7: 1 to about 9: 1.
  • the binder is HPMC
  • the slow beads contain fenofibrate and HPMC in a ratio of fenofibrate: HPMC of about 8: 1.
  • the slow beads additionally comprise from 0% to about 0.25% by weight of sodium lauryl sulfate, and are preferably free of sodium lauryl sulfate.
  • Fenofibrate which is a prodrug of fenofibric acid
  • the fenofibrate powder may be fenofibrate Form I as disclosed in U.S. Patent Publication 2009/0149533; fenofibrate Form II as disclosed in U.S. Patent Publication 2009/0149533; amorphous fenofibrate; hydrates or solvates of fenofibrate, or a mixture thereof.
  • Fenofibrate may be partially or completely replaced with fenofibric acid; pharmaceutically acceptable salts of fenofibric acid; CI to C5 esters or prodrugs of fenofibric acid, or a mixture thereof.
  • the fast and slow beads are made using micronized fenofibrate with a weight- average particle diameter (D50) of between 1 and 15 microns, preferably between 4 and 10 microns.
  • D50 weight- average particle diameter
  • the fast and slow beads are made using micronized fenofibrate where at least 99% of the fenofibrate particles have a particle diameter of less than 50 microns.
  • sugar spheres were used as the base substrate onto which the drug suspension was sprayed.
  • the drug suspension was sprayed onto the sugar spheres in a fluidized bed fitted with a ROTOR Insert.
  • the sugar spheres had a 20-25 mesh particle size distribution, providing a uniform surface area for drug layering.
  • the micronized fenofibrate used in the following examples had a weight average particle size D50 of between 5 and 7 microns, with at least 99% of particles having a particle size of ⁇ 50 microns (D99); at least 90% of particles having a particle size of ⁇ 15 microns (D90); and no more than 10% of particles having a particle size of ⁇ 1 micron (D10).
  • Purified water was selected as a solvent for preparation of the drug suspension, as it provides a suitable medium for dissolving the hypromellose binder and suspending the micronized fenofibrate drug substance.
  • Hypromellose (Pharmacoat® 603) was used as a binder in the drug suspension, as it aids in adhering the drug to the sugar sphere substrate during processing.
  • SLS Sodium lauryl sulfate
  • Sodium lauryl sulfate is a commonly used excipient in solid oral dosage forms to enhance wetting and improve drug dissolution rate. This excipient is employed to enhance the aqueous wettability of fenofibrate in the drug layering suspension and to enhance the drug release from the high bioavailability, or fast, drug layered beads.
  • Sodium lauryl sulfate was not used in the slow beads in the following examples, resulting in reduced drug release from the slow beads.
  • formulations disclosed herein were administered to healthy adult volunteers in bioequivalence studies under fasting and fed conditions. The bioavailability achieved with the formulations disclosed herein is comparable to the bioavailability achieved with the administration of Lupin's ANTARA® capsules, where the ANTARA® capsules contain a single population of granules having a defined concentration of fenofibrate.
  • the formulations disclosed herein include two populations of fenofibrate beads, including fast beads which have a higher bioavailability than the beads in ANTARA® capsules, and slow beads which have a lower bioavailability than the beads in ANTARA® capsules.
  • Manufacture of Fenofibrate Capsules proceeds via encapsulation of Fenofibrate Intermediate Beads blend using two separate capsule filling stations.
  • Filling station I is used to encapsulate the Fast Fenofibrate Intermediate Beads and the Filling station II is used to encapsulate the Slow Fenofibrate Intermediate Beads.
  • the manufacturing process was shown to provide a finished product with acceptable assay and content uniformity characteristics.
  • the drug layer suspension in this invention is manufactured using a high speed homogenizer mixer (Ross Model HSM 105, attached with a rotor/stator mixing blade used for the large scale manufacturing).
  • a high speed homogenizer mixer Ross Model HSM 105
  • several different types of mixer/disperser mixing head attachments were evaluated: slotted rotor/stator disperser, saw tooth disperser, slotted stator, and a fine screen stator with slotted disperser.
  • Table 1 summarizes the formulation compositions and the drug release characteristics from these experiments. All formulations processed well and their drug release characteristics were similar, indicating that mixer type has no impact on formulation performance. Based on this evaluation, the rotor/stator configuration was chosen for the manufacture of the drug layering suspension.
  • the process requires the suspension to be mixed with a homogenizer mixer for a minimum of 8 hours prior to drug layering, with continuous agitation of the suspension maintained throughout the drug layering process.
  • the fluidization pattern in the rotor processor can be best characterized as a spiraling helix. Three factors act on the beads or pellets or particles (materials) to produce this flow pattern.
  • the rotating disk of the ROTOR insert provides centrifugal force which forces the rotating materials toward the wall of the processing chamber at the periphery of the rotor insert, while conditioned upward airflow through the rotor gap develops a vertical force causing the materials to become fluidized.
  • the fluidization air pushes the moving materials upward into the expansion chamber until gravity overcomes the upward air velocity and the material falls toward the center of the disk where there is little air movement.
  • the drug layer suspension is sprayed tangentially onto the rotating particles, while heated process air causes the applied drug layer suspension to dry before the particles move again into the spraying zone. This cyclical process is repeated many hundreds of times until the appropriate quantity of solids are applied to the rotating core substrate (material).
  • the efficiency of the drug layering process is dependent on the relationship between particle movement within the processor, drug layering suspension spray rate and the rate of solvent evaporation.
  • the movement of the particles during rotor drug layering process is dependent on rotor speed and air flow. Rotor speed is considered a critical parameter since it can affect the integrity of the beads. Slow speeds can lead to product agglomeration while excessive speeds can cause attrition. Rotor speed is adjusted to maintain proper particle movement as the weight of the batch increases during drug layering process. Once proper movement of the particle bed is established, the deposition of drug layering solids onto the core substrate is controlled by the rate at which drug layering suspension is applied to core beads or pellets, and the rate at which solvent is removed from the system.
  • Two formulations of fenofibrate containing beads were prepared. Each formulation was prepared by spraying a fenofibrate suspension onto sugar spheres having a size of 35 to 45 mesh in a fluidized bed. In one formulation (designated X07-047- 58A1), the drug suspension included fenofibrate and HPMC in a ratio of 4:1, while in the other formulation (designated X07-047-62A1), the drug suspension included fenofibrate and HPMC in a ratio of 2.4: lwere evaluated. The amounts of the various ingredients are set forth in Table 3 below. The bead formulations are prepared in a fluidized bed by spraying a water-based suspension of micronized fenofibrate, HPMC, and sodium lauryl sulfate onto the sugar spheres.
  • Dissolution condition 1000 mL purified water, 0.01 M sodium lauryl sulfate,
  • a formulation containing fenofibrate and HPMC in a ratio of 4: 1 was evaluated.
  • the formulation additionally contained 2%, by weight of the formulation, of the anionic surfactant SLS, as seen in Table 7.
  • FL-M-60 large scale fluid bed dryer
  • Simethicone was incorporated to the drug layering suspension at a low level (0.044 %w/w) to minimize foaming during preparation.
  • the dried beads were blended with micronized talc, screened to remove agglomerates, and machine encapsulated into the two piece hard gelatin capsules
  • Table 7 (2% SLS, 4: 1 Drug:HPMC) is comparable to the drug release rate of the branded product ANTARA®. Both formulations release 54% of the incorporated fenofibrate in 10 minutes; 92% to 93% of the incorporated fenofibrate in 30 minutes; and substantially all of the incorporated fenofibrate in 60 minutes. [0071] The formulation of Table 7 was assessed in a pilot bioequivalence study, and compared to ANTARA® Capsules. Both the formulation of Table 7 and the ANTARA® Capsules contained 130 mg fenofibrate. The pilot bioequivalence study was an open- label, single-dose, randomized, two-period, two-treatment crossover study, using 24 normal healthy subjects. A summary of the pharmacokinetic data is presented in Table 9.
  • bioequivalence between a branded product and a generic equivalent.
  • bioequivalence depends on several natural log transformed parameters associated with the rate and extent of absorption. Specifically, the entire 90% confidence interval for the ratio of the test to reference area under the curve from zero to the last detectable concentration, AUCL, must fall between 80 and 125% of the corresponding AUCL of the branded product for therapeutic equivalence. Additionally, the entire 90% confidence interval for the ratio of the test to reference maximum plasma concentration, Cpeak, must also fall between 80 and 125% of the corresponding Cpeak of the branded product for therapeutic equivalence to be declared.
  • the Cpeak parameter for the formulation of Table 7 is 138% of the corresponding value for the branded product, with a 90% confidence interval of 128.1 %- 155%. This result falls outside the FDA's desired confidence interval ratio of 80%- 125%. Accordingly, the formulation of Table 7 exhibits higher bioavailability under fasting conditions than the reference product ANTARA®. In this in vivo evaluation, the formulation of Table 7 used smaller size beads (35-45 mesh) than ANTARA® capsules, which might have caused increased bioavailability due to larger surface area of the dosage forms.
  • Table 10 is faster than the drug release rate of the branded product ANTARA®.
  • Formulation #1000374 containing 2% sodium lauryl sulfate, releases 64% of the incorporated fenofibrate in 10 minutes; and substantially all of the incorporated fenofibrate in 30 minutes.
  • ANTARA® in contrast, releases 54% of the incorporated fenofibrate in 10 minutes; and 93% of the incorporated fenofibrate in 30 minutes.
  • Formulation #1000375 containing 0.5% sodium lauryl sulfate, is more closely comparable to ANTARA® capsules, releasing 61% of the incorporated fenofibrate in 10 minutes; 94% of the incorporated fenofibrate in 30 minutes; and substantially all of the incorporated fenofibrate in 60 minutes.
  • Formulation X07-047-82A1 containing 6.5% w/w Pharmacoat 603 with no sodium lauryl sulfate was manufactured in a large scale equipment as lot 1000442 using Size#0EL capsules shell and evaluated in a bioequivalence study versus ANTARA® capsules. Table 16 describes this formulation.
  • the capsules of Table 16 release the drug more slowly than the comparative ANTARA® capsules. After 10 minutes, the comparative ANTARA® capsules released 54% of the drug, while the capsules of Table 14 released onlyl4% of the drug. Additionally, the capsules of Table 14 were assessed in a bioequivalence study versus ANTARA® Capsules, 130 mg in an open-label, single-dose, randomized, two-period, two-treatment crossover study using 32 normal healthy subjects (27 completed the study). The methodology was similar to the methodology used in Example 3. A summary of the pharmacokinetic data from this study is presented in Table
  • the capsules of Table 16 exhibited poor bioavailability under fasting conditions due to a low AUCL and Cpeak.
  • the results of Table 18 indicate that the capsules of Table 16, containing fenofibrate and HPMC in a ratio of 8: 1 and no sodium lauryl sulfate, exhibited low absorption (AUCL) compared to ANTARA® capsules.
  • the capsules of Table 16 showed between 53% and 59%% of the absorption (AUCL) observed with the branded product, with a confidence interval of 90%.
  • the Cpeak parameter for capsules of Table 16 has a 90% confidence interval of 45% to 53% when compared to the branded product. This result falls outside the FDA's desired confidence interval ratio of 80%- 125%, and indicates that the capsules of Table 16 are not bioequivalent to ANTARA® capsules.
  • Type B beads 20 is also substantially slower than a capsule prepared using Type B beads alone, where the Type B beads contain fenofibrate and HPMC in a ratio of 4.1: 1, with 2% sodium lauryl sulfate.
  • Treatment B Lot 1000530 contains 75% Fast Beads (2%SLS) and 25% Slow Beads (No SLS); Dose: lx
  • Treatment C Antara Capsules, Lot : B08017 ; Dose: 1 x 130 mg ; Oscient/Lupin
  • a large scale batch, Formulation#1000596 was manufactured using the Formulation composition of 1000530 (shown in Table 20).
  • This capsule contains two different types of Fenofibrate Intermediate Beads, one containing no surfactant (Fenofibrate Intermediate Beads, Type C, 520 mg/g) and the other containing sodium lauryl sulfate as a surfactant (Fenofibrate Intermediate Beads, Type B).
  • Each capsule contains 25%w/w Fenofibrate Intermediate Beads Type C (520 mg/g) and 75%w/w Fenofibrate Intermediate Beads Type B which corresponds to theoretical fill weights of 62.5 mg and 187.725 mg, respectively.
  • the actual fill weight of each bead is adjusted based on the potency factor assigned to each bead prior to encapsulation.
  • Each bead type was filled into the capsule shell using a separate dosing station during encapsulation.
  • 100596, 130 mg are bioequivalent to ANTARA® Capsules, 130 mg, following a single, oral 130 mg (1 x 130mg capsule) dose administered under fasting and post-prandial conditions.
  • a summary of the pharmacokinetic data from this study is presented in Table 23 and Table 24.
  • Figure 5 and Figure 6 display the pharmacokinetic profile, specifically plasma concentration of fenofibrate over time, for Capsules of Lot. 100596, 130 mg which are bioequivalent to ANTARA® Capsules, 130 mg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne diverses compositions de fénofibrate comprenant une pluralité de premiers granules présentant une biodisponibilité élevée in vivo, et une pluralité de seconds granules présentant une faible biodisponibilité in vivo. Les premiers granules peuvent comprendre du fénofibrate, de 0,3 % à 10 % en poids des premiers granules d'un premier tensioactif, et un premier dérivé cellulosique hydrodispersable ou hydrosoluble, et les seconds granules peuvent comprendre du fénofibrate, de 0 % à 0,25 % en poids des seconds granules d'un second tensioactif, et un second dérivé cellulosique hydrodispersable ou hydrosoluble.
EP12880074.5A 2012-06-25 2012-06-25 Formulation de fénofibrate Pending EP2863890A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/043971 WO2014003706A1 (fr) 2012-06-25 2012-06-25 Formulation de fénofibrate

Publications (2)

Publication Number Publication Date
EP2863890A1 true EP2863890A1 (fr) 2015-04-29
EP2863890A4 EP2863890A4 (fr) 2015-12-09

Family

ID=49783663

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12880074.5A Pending EP2863890A4 (fr) 2012-06-25 2012-06-25 Formulation de fénofibrate

Country Status (5)

Country Link
EP (1) EP2863890A4 (fr)
BR (1) BR112014032579A2 (fr)
CA (1) CA2877901A1 (fr)
IN (1) IN2014DN11044A (fr)
WO (1) WO2014003706A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101925590B1 (ko) * 2016-08-30 2018-12-05 대원제약 주식회사 개선된 생체이용률을 갖는 페노피브릭산 제제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US7863331B2 (en) 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
KR20070104447A (ko) * 2005-02-10 2007-10-25 라이프사이클 파마 에이/에스 페노피브레이트 및 ＨＭＧ-ＣｏＡ 리덕타제 억제제의 고정용량 배합물을 포함하는 안정한 약학 조성물
US20090252787A1 (en) * 2006-07-28 2009-10-08 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
FR2940118B1 (fr) * 2008-12-24 2013-08-09 Ethypharm Sa Formulation pharmaceutique de fenofibrate nanonise
US20100166857A1 (en) * 2008-12-30 2010-07-01 Dong Yan Pharmaceutical dosage forms and methods of manufacturing same
US20110217369A1 (en) * 2009-09-03 2011-09-08 Ranbaxy Laboratories Limited Fenofibrate compositions

Also Published As

Publication number Publication date
CA2877901A1 (fr) 2014-01-03
IN2014DN11044A (fr) 2015-09-25
BR112014032579A2 (pt) 2017-06-27
WO2014003706A1 (fr) 2014-01-03
EP2863890A4 (fr) 2015-12-09

Similar Documents

Publication Publication Date Title
JP4789806B2 (ja) パントプラゾール多粒子処方
JP6368242B2 (ja) ４０−ｏ−（２−ヒドロキシ）エチル−ラパマイシンを含む医薬組成物
JP6356215B2 (ja) エベロリムスを含む医薬組成物
JP2002523443A (ja) オメプラゾール製剤
JP2011063611A (ja) シロスタゾール製剤
JP4748839B2 (ja) シロスタゾール製剤
EP1729741A2 (fr) Systeme d'administration de medicaments polymeres pour des medicaments hydrophobes
CN110664780B (zh) 延迟释放型半胱胺珠粒调配物，以及其制备及使用方法
UA82268C2 (uk) Гранули, що містять гідрохлорид венлафаксину, та спосіб їх виготовлення
WO2013123965A1 (fr) Formulation pharmaceutique à dose fixe
US9949933B2 (en) Fenofibrate formulation
US8722083B2 (en) Fenofibrate formulation
CN111617258A (zh) 一种制备阿比特龙或其衍生物药物组合物的方法及其应用
CN114146089B (zh) 含依非韦伦、替诺福韦和恩曲他滨的药物组合物
EP2863890A1 (fr) Formulation de fénofibrate
KR20230067636A (ko) 듀테트라베나진을 포함하는 다중미립자 제형
JP3929522B2 (ja) 難水溶性薬物の徐放性製剤
ES2954168T3 (es) Composiciones autoemulsionantes de ingredientes farmacéuticos activos débilmente ionizables o no ionizables
JP5171626B2 (ja) 水難溶性薬物含有球形素顆粒の製造方法
US20100034887A1 (en) Bursting Pellets
WO2018130943A1 (fr) Composition pharmaceutique orale de lurasidone et sa préparation
JP5919173B2 (ja) 徐放性塩酸アンブロキソール口腔内崩壊錠
WO2019160120A1 (fr) Procédé de fabrication de particules contenant un médicament
WO2022144919A1 (fr) Compositions pharmaceutiques à libération prolongée de riociguat
HU227115B1 (en) Pellets containing pyridazinone derivative

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151111

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/50 20060101ALI20151105BHEP

Ipc: A61K 9/48 20060101ALI20151105BHEP

Ipc: A61K 9/16 20060101ALI20151105BHEP

Ipc: A61K 9/14 20060101AFI20151105BHEP

Ipc: A61P 3/06 20060101ALI20151105BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

R17P Request for examination filed (corrected)

Effective date: 20150126

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180131

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0009140000

Ipc: A61K0009160000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/06 20060101ALI20240403BHEP

Ipc: A61K 9/50 20060101ALI20240403BHEP

Ipc: A61K 9/48 20060101ALI20240403BHEP

Ipc: A61K 9/16 20060101AFI20240403BHEP

INTG Intention to grant announced

Effective date: 20240425